NASDAQ:ODT - Odonate Therapeutics Stock Price, Price Target & More

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics Inc (NASDAQ:ODT) posted its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.69) EPS for the quarter, topping the Zacks' consensus estimate of ($0.85) by $0.16. View Odonate Therapeutics' Earnings History.

3 brokerages have issued 12-month price targets for Odonate Therapeutics' stock. Their forecasts range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' share price to reach $33.50 in the next twelve months. This suggests a possible upside of 44.6% from the stock's current price. View Analyst Ratings for Odonate Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Odonate Therapeutics include Akcea Therapeutics (AKCA), Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), TESARO (TSRO), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Puma Biotechnology (PBYI) and Prestige Brands (PBH).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics' lock-up period expired on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its public offering on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

News coverage about ODT stock has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Odonate Therapeutics earned a news impact score of 0.16 on Accern's scale. They also assigned news coverage about the company an impact score of 46.60 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $23.17.

Odonate Therapeutics has a market capitalization of $639.13 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]